Alzheimer’s disease (AD), the commonest cause of dementia, represents a significant cost to UK society. This analysis describes resource utilisation, costs and clinical outcomes in non-institutionalised patients with AD in the UK. The GERAS prospective observational study assessed societal costs associated with AD for patients and caregivers All patients enrolled had an informal caregiver willing to participate in the study
It showed that AD is a costly disease, with costs increasing with disease severity, even when managed in the community: informal caregiver costs represented the main contributor to societal costs.
Click here to access the article. An OpenAthens login is required. Alternatively call 0161 291 5778 or email Academy Library for a copy of the article.